Excelsior Biopharma Capital Reinvestment Ratio
Excelsior Biopharma capital reinvestment ratio. Excelsior Biopharma (6496) has a Capital Reinvestment Ratio of 3.80x as of June 2025, meaning it reinvests 4% of its operating cash flow (NT$3.80 Million) in capital expenditures (NT$14.44 Million). Check cash flow reinvestment rate of Excelsior Biopharma to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Excelsior Biopharma (2017–2022)
Capital reinvestment ratio of Excelsior Biopharma from 2017 to 2022. This chart tracks Excelsior Biopharma's Capital Reinvestment Ratio across 5 annual periods. Also explore Excelsior Biopharma equity growth rate to track the company's year-over-year net asset growth rate.
Excelsior Biopharma Capital Reinvestment Ratio by Year (2017–2022)
Excelsior Biopharma capital reinvestment ratio by year from 2017 to 2022. For the full cash flow conversion analysis, see 6496 cash flow conversion.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2022 | 1.42x | NT$5.49 Million | NT$7.78 Million | ▲ +2652.7% |
| 2021 | 0.05x | NT$55.82 Million | NT$2.88 Million | ▲ +131.1% |
| 2020 | 0.02x | NT$520.81 Million | NT$11.62 Million | ▼ -70.3% |
| 2018 | 0.08x | NT$126.92 Million | NT$9.54 Million | ▲ +45.2% |
| 2017 | 0.05x | NT$349.47 Million | NT$18.10 Million | — |